Universe Pharmaceuticals INC (NASDAQ:UPC) Short Interest Update

Universe Pharmaceuticals INC (NASDAQ:UPC) was the recipient of a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 35,401 shares, an increase of 454.7% from the July 30th total of 6,382 shares. Currently, 1.7% of the company’s shares are short sold. Based on an average daily trading volume, of 2,816,444 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Universe Pharmaceuticals Stock Down 6.2%

Shares of NASDAQ UPC opened at $5.03 on Wednesday. Universe Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $17.96. The company has a quick ratio of 3.90, a current ratio of 4.05 and a debt-to-equity ratio of 0.04. The stock has a fifty day simple moving average of $4.95 and a 200-day simple moving average of $3.65.

Universe Pharmaceuticals (NASDAQ:UPC) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($1.38) earnings per share (EPS) for the quarter. The company had revenue of $4.52 million during the quarter.

Universe Pharmaceuticals Company Profile

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.